Navidea Biopharmaceuticals Company Profile (NYSEMKT:NAVB)

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSEMKT
  • Symbol: NAVB
  • CUSIP: 63937X10
Key Metrics:
  • Previous Close: $0.53
  • 50 Day Moving Average: $0.5278
  • 200 Day Moving Average: $0.8441
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.68
  • P/E Growth: 0.0000
  • Market Cap: $82.42M
  • Outstanding Shares: 155,383,000
  • Beta: 0.27
Additional Links:
Companies Related to Navidea Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Navidea Biopharmaceuticals (NYSEMKT:NAVB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Show:
DateFirmActionRatingPrice TargetDetails
10/15/2014AegisReiterated RatingHold -> PositiveView Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016        
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.08)$0.90 million$0.75 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Current Year EPS Consensus Estimate: $-0.0800 EPS
Next Year EPS Consensus Estimate: $-0.0300 EPS

Dividends

Dividend History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.00View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.00View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
DateHeadline
sbwire.com logoGlobal Malignant Melanoma Market (Skin Cancer) with Focus on Nevisense System 2020 Analysis & Forecasts (NYSEMKT:NAVB)
www.sbwire.com - August 23 at 6:33 PM
News IconResearch details developments in the Global malignant melanoma market with focus on nevisense system from 2015 to 2020 (NYSEMKT:NAVB)
www.whatech.com - August 23 at 10:48 AM
News IconStock Tracking Lower for the Quarter: Navidea Biopharmaceuticals, Inc (:NAVB) - Post News (NYSEMKT:NAVB)
www.kentuckypostnews.com - August 20 at 6:05 PM
finance.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Financials (NYSEMKT:NAVB)
finance.yahoo.com - August 19 at 6:17 PM
finance.yahoo.com logoEdited Transcript of NAVB earnings conference call or presentation 4-Aug-16 12:30pm GMT (NYSEMKT:NAVB)
finance.yahoo.com - August 15 at 6:40 PM
News IconSizzling Healthcare Stock Alert: Navidea Biopharmaceuticals, Inc's (NAVB) - Hot Stocks Point (NYSEMKT:NAVB)
www.hotstockspoint.com - August 15 at 8:35 AM
capitalcube.com logoETF’s with exposure to Navidea Biopharmaceuticals, Inc. : August 12, 2016 (NYSEMKT:NAVB)
www.capitalcube.com - August 12 at 6:27 PM
News IconStock Update on Navidea Biopharmaceuticals, Inc (:NAVB) - Duncan Research (NYSEMKT:NAVB)
www.duncanindependent.com - August 11 at 6:46 PM
publicnow.com logoNavidea Biopharmaceuticals Announces 2016 Annual Meeting Results (NYSEMKT:NAVB)
www.publicnow.com - August 11 at 6:46 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Event (NYSEMKT:NAVB)
biz.yahoo.com - August 11 at 6:46 PM
News IconActive Stocks in 'How' and 'Why'- Navidea Biopharmaceuticals (NYSE:NAVB), IAMGOLD (NYSE:IAG), Weibo (NASDAQ ... - Seneca Globe (NYSEMKT:NAVB)
www.senecaglobe.com - August 10 at 6:47 PM
streetinsider.com logoNavidea Biopharma (NAVB) to Delay 10-Q - StreetInsider.com (NYSEMKT:NAVB)
www.streetinsider.com - August 10 at 6:47 PM
bizjournals.com logoNavidea finally set to unload Alzheimer's drug, ending suitor's lawsuit (NYSEMKT:NAVB)
www.bizjournals.com - August 9 at 6:38 PM
4-traders.com logoNavidea Biopharmaceuticals : Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694 (NYSEMKT:NAVB)
www.4-traders.com - August 8 at 6:35 PM
publicnow.com logoNavidea Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694 (NYSEMKT:NAVB)
www.publicnow.com - August 8 at 6:35 PM
cnbc.com logoNavidea reports 2Q loss (NYSEMKT:NAVB)
www.cnbc.com - August 4 at 9:33 AM
twst.com logoNavidea Biopharmaceuticals Inc.: Navidea Reports Second Quarter 2016 Financial Results (NYSEMKT:NAVB)
www.twst.com - August 4 at 9:33 AM
biz.yahoo.com logoQ2 2016 Navidea Biopharmaceuticals Inc Earnings Release - Before Market Open (NYSEMKT:NAVB)
biz.yahoo.com - August 4 at 9:33 AM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Stateme (NYSEMKT:NAVB)
biz.yahoo.com - August 4 at 9:33 AM
publicnow.com logoNavidea Reports Second Quarter 2016 Financial Results (NYSEMKT:NAVB)
www.publicnow.com - August 4 at 9:33 AM
finance.yahoo.com logo7:29 am Navidea Biopharma reports Q2 results, revs up 88% (NYSEMKT:NAVB)
finance.yahoo.com - August 4 at 9:33 AM
publicnow.com logoNavidea Biopharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016 (NYSEMKT:NAVB)
www.publicnow.com - July 28 at 10:38 AM
bizjournals.com logoJust what is this drug Navidea is fighting for? (NYSEMKT:NAVB)
www.bizjournals.com - July 27 at 6:43 PM
News IconNavidea gains IRB approval for technetium Tc 99m tilmanocept clinical trial (NYSEMKT:NAVB)
www.healio.com - July 25 at 10:51 AM
equities.com logoNavidea Biopharmaceuticals Inc. (NAVB) Drops 5.48% on July 21 - Equities.com (NYSEMKT:NAVB)
www.equities.com - July 23 at 10:16 AM
News IconWhich way Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) earnings may go - The Voice Registrar (NYSEMKT:NAVB)
voiceregistrar.com - July 23 at 10:15 AM
News IconNavidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) Short Interest Decreased By 9.18% - Consumer Eagle (NYSEMKT:NAVB)
www.consumereagle.com - July 22 at 6:14 PM
equities.com logoNavidea Biopharmaceuticals Inc. (NAVB) Jumps 8.71% on July 19 - Equities.com (NYSEMKT:NAVB)
www.equities.com - July 22 at 6:14 PM
capitalcube.com logoETF’s with exposure to Navidea Biopharmaceuticals, Inc. : July 20, 2016 (NYSEMKT:NAVB)
www.capitalcube.com - July 20 at 12:44 PM
streetinsider.com logoNavidea Biopharma (NAVB) Approved by IRB to Conduct Lymphoseek Studying in RA Identification - StreetInsider.com (NYSEMKT:NAVB)
www.streetinsider.com - July 19 at 10:21 AM
News IconHot Biotech Stocks Recap: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Calithera Biosciences, Inc. (NASDAQ ... - The Voice Registrar (NYSEMKT:NAVB)
voiceregistrar.com - July 19 at 10:21 AM
News IconShares Moving Down on the Week: Navidea Biopharmaceuticals, Inc (:NAVB) - Engelwood Daily (NYSEMKT:NAVB)
www.engelwooddaily.com - July 17 at 5:48 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Navidea Biopharmaceuticals, Inc. (NAVB) - Fiscal Standard (NYSEMKT:NAVB)
www.fiscalstandard.com - July 17 at 5:48 PM
news.cmlviz.com logoNavidea Biopharmaceuticals, Inc Stock Momentum Hits Extreme Weakness - CML News (NYSEMKT:NAVB)
news.cmlviz.com - July 16 at 9:42 AM
News IconShares Experiencing a Downtrend: Navidea Biopharmaceuticals, Inc (:NAVB) - TGP (NYSEMKT:NAVB)
telanaganapress.com - July 16 at 9:42 AM
news.cmlviz.com logoNavidea Biopharmaceuticals, Inc (AMEX:NAVB) Fundamental Star Rating Report - CML News (NYSEMKT:NAVB)
news.cmlviz.com - July 13 at 6:45 PM
equities.com logoNavidea Biopharmaceuticals Inc. (NAVB) Hits New 52-week Low During July 11 Session - Equities.com (NYSEMKT:NAVB)
www.equities.com - July 13 at 9:20 AM
ftsenews.co.uk logoNavidea Biopharmaceuticals, Inc. (NAVB) Updated Price Targets - FTSE News (NYSEMKT:NAVB)
www.ftsenews.co.uk - July 12 at 6:39 PM
equities.com logoNavidea Biopharmaceuticals Inc. (NAVB) Drops 5.15% on July 11 - Equities.com (NYSEMKT:NAVB)
www.equities.com - July 12 at 6:39 PM
News IconNavidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) Shorted Shares Increased 3.73% After Market Selling - Consumer Eagle (NYSEMKT:NAVB)
www.consumereagle.com - July 12 at 10:43 AM
streetupdates.com logoStocks Movements to Focus: Shire plc (NASDAQ:SHPG) , Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) - Street Updates (NYSEMKT:NAVB)
www.streetupdates.com - July 12 at 10:43 AM
ftsenews.co.uk logoNew Broker Ratings For Navidea Biopharmaceuticals, Inc. (NAVB) - FTSE News (NYSEMKT:NAVB)
www.ftsenews.co.uk - July 7 at 9:16 AM
News IconNavidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) Shorted Shares Increased By 3.73% - Press Telegraph (NYSEMKT:NAVB)
presstelegraph.com - July 7 at 9:16 AM
insidermonkey.com logoPlatinum Partners to Shut Down Main Fund; Here Are Its 5 Stock Picks (NYSEMKT:NAVB)
www.insidermonkey.com - July 5 at 9:57 AM
fiscalstandard.com logoNavidea Biopharmaceuticals, Inc. (NAVB) Broker Price Targets For The Coming Week - Fiscal Standard (NYSEMKT:NAVB)
www.fiscalstandard.com - July 4 at 5:44 PM
News IconShare Performance Recap for: Navidea Biopharmaceuticals, Inc (:NAVB) - Press Telegraph (NYSEMKT:NAVB)
presstelegraph.com - July 4 at 5:44 PM
News IconCompany Stock Lower on the Week Navidea Biopharmaceuticals, Inc (:NAVB) - Engelwood Daily (NYSEMKT:NAVB)
www.engelwooddaily.com - July 2 at 6:02 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Navidea Biopharmaceuticals, Inc. (NAVB) - Fiscal Standard (NYSEMKT:NAVB)
www.fiscalstandard.com - July 2 at 9:10 AM
kcregister.com logoBiotech New Lows: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), TG Therapeutics, Inc. (NASDAQ:TGTX ... - KC Register (NYSEMKT:NAVB)
www.kcregister.com - July 1 at 9:13 AM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSEMKT:NAVB)
biz.yahoo.com - June 29 at 4:55 PM

Social


Last Updated on 8/26/2016 by MarketBeat.com Staff